Contact the Editorial Desk

Editorial correspondence

The mapmaker welcomes notes on the record itself: a citation quoted loosely, a clinical trial that has posted new results, a regulatory update that shifts an approval status, or a peer-reviewed study on semaglutide, tirzepatide, or retatrutide that belongs on the references page. A correction that makes the chart more accurate or more current is the most valuable message this desk gets, and each one is read and weighed with care.

The notes easiest to act on name three things: which page, the exact passage in question, and the supporting reference — a DOI or PubMed identifier wherever you have one. In that shape, a proposed change can be checked against its source before the map is redrawn.

Editorial mailbox: editors@peptidemundo.com

Beyond the atlas's reach

So no message goes ignored for the wrong reason, a few requests sit past the edge of this map. Because Peptide Mundo charts and reports the literature rather than practicing medicine or selling anything, it can't:

• Weigh in on, endorse, or advise human use of any peptide charted here.
• Name a dose, schedule, or route for any individual.
• Judge whether a finding from a cited trial fits a specific person's situation.
• Sell, source, suggest, or help track down a compound from any supplier.
• Point the way to prescription medicines outside a licensed prescriber-patient relationship.
• Guide athletes under anti-doping rules, since some compounds in this class carry pharmacovigilance profiles that brush up against WADA monitoring.

Semaglutide and tirzepatide are prescription medicines; retatrutide is investigational and not legally available outside clinical trials. Anyone seeking medical guidance should bring it to a licensed clinician in their jurisdiction. Replies aren't guaranteed and can lag; the mailbox is checked now and then.